The stock's near-term direction hinges on FDA's response to the submitted sunRIZE datasets, not the financials. Monitor for FDA feedback on whether the CGM data supports a regulatory path forward despite the missed primary endpoint. The upLIFT tumor HI readout in H2 2026 is the next binary catalyst.
Price Chart
Executive Summary
Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the $18.9M loss ($-0.27/share) a year ago, driven by lower R&D and G&A expenses. The key catalyst is the expanded CGM analysis from the Phase 3 sunRIZE study presented at PES, showing nominally significant glycemic improvements, though the primary endpoint was previously missed. The stock will move on the FDA's independent evaluation of this data, not the financials.
Key Financial Metrics
Key Facts
- Net loss of $16.2M for Q3 fiscal 2026, improved from $18.9M loss in Q3 fiscal 2025
- EPS of $-0.16 vs $-0.27 year ago; no consensus estimate provided for this quarter
- Cash and investments of $120.3M as of March 31, 2026, down from $167.9M at June 30, 2025
- Expanded CGM analysis from Phase 3 sunRIZE study showed nominally significant reductions in hypoglycemia vs placebo across multiple endpoints
- FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation after March 2026 Type B meeting
- Topline results from upLIFT tumor HI study expected in H2 2026
Financial Impact
No revenue; net loss improved by $2.7M YoY to $16.2M; cash burn of ~$47.6M over 9 months
Risk Factors
- FDA may not accept CGM-based endpoints as sufficient for approval after primary endpoint miss
- Cash runway of $120.3M supports operations but burn rate implies ~2 years of funding without additional capital
- No revenue and pre-commercial stage means stock is entirely driven by clinical/regulatory milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059392 |
| Document: tm2614169d1_8k.htm | 0001104659-26-059392 |
| Document: 0001104659-26-059392-index-headers.html | 0001104659-26-059392 |
| Document: 0001104659-26-059392-index.html | 0001104659-26-059392 |
| Document: 0001104659-26-059392.txt | 0001104659-26-059392 |
| 8-K Data (Synthetic) | 0001104659-26-059392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEF 14A | $3.86 | awaiting T+20 | — | $3.82 (−1.04%) |
Oct 14, 2026 12d ago | 8-K | $3.90 | awaiting T+20 | — | $3.82 (−2.05%) |
Oct 5, 2026 21d ago | 8-K | $4.33 | awaiting T+20 | — | $3.82 (−11.78%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $3.82 (+2.05%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $3.82 (+2.05%) |
Jul 21, 2026 13w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $3.82 (−24.95%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $3.82 (−1.04%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $3.82 (−15.30%) |
Jun 2, 2026 20w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $3.82 (−4.50%) |
May 12, 2026 23w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $3.82 (+14.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers